We are live on ! Find out more
MREO

Mereo BioPharma
MREO

58 hedge funds and large institutions have $43M invested in Mereo BioPharma in 2023 Q1 according to their latest regulatory filings, with 7 funds opening new positions, 15 increasing their positions, 14 reducing their positions, and 10 closing their positions.

New
Increased
Maintained
Reduced
Closed

7% more repeat investments, than reductions

Existing positions increased: 15 | Existing positions reduced: 14

0.12% less ownership

Funds ownership: 9.85% → 9.73% (-0.12%)

5% less funds holding

Funds holding: 61 → 58 (-3)

7% less capital invested

Capital invested by funds: $46.2M → $43M (-$3.16M)

30% less first-time investments, than exits

New positions opened: 7 | Existing positions closed: 10

Holders
58
Holders Change
-3
Holders Change %
-4.92%
% of All Funds
0.92%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
7
Increased
15
Reduced
14
Closed
10
Calls
$54K
Puts
–
Net Calls
+$54K
Net Calls Change
+$48K

Top Buyers

Rank Fund Capital Flow
1
6CM
683 Capital Management
New York
+$1.69M
2
Millennium Management
Millennium Management
New York
+$1.07M
3
Citigroup
Citigroup
New York
+$1.02M
4
BFM
Boothbay Fund Management
New York
+$385K
5
JGC
J. Goldman & Co
New York
+$267K

Top Sellers

Rank Fund Capital Flow
1
O
OrbiMed
New York
-$2.57M
2
AG
Artal Group
Luxembourg
-$1.13M
3
OCA
Octagon Capital Advisors
New York
-$750K
4
MAM
Monaco Asset Management
Monaco
-$660K
5
Renaissance Technologies
Renaissance Technologies
New York
-$307K
Name Holding Trade Value Shares
Change 		Change in
Stake
AF
51
Allworth Financial
California
$1.06K – – –
SIA
52
Sit Investment Associates
Minnesota
$1K – – –
BNP Paribas Financial Markets
53
BNP Paribas Financial Markets
France
$397 – – –
NECFA
54
New England Capital Financial Advisors
Connecticut
$213 – – –
Wells Fargo
55
Wells Fargo
California
$162 -$1 -1 -0.4%
PMFA
56
Plante Moran Financial Advisors
Michigan
$34 – – –
US Bancorp
57
US Bancorp
Minnesota
$9 – – –
AG
58
Artal Group
Luxembourg
– -$1.13M -1,500,000 Closed
OCA
59
Octagon Capital Advisors
New York
– -$750K -1,000,000 Closed
E
60
Ergoteles
New York
– -$99.6K -132,784 Closed
GCP
61
GSA Capital Partners
United Kingdom
– -$55K -72,740 Closed
Envestnet Asset Management
62
Envestnet Asset Management
Illinois
– -$28K -37,367 Closed
VF
63
Virtu Financial
New York
– -$15K -19,745 Closed
T
64
TCWP
Ohio
– -$14.3K -19,000 Closed
TRCT
65
Tower Research Capital (TRC)
New York
– -$11K -15,129 Closed
Simplex Trading
66
Simplex Trading
Illinois
– -$5.57K -6,190 Closed
Royal Bank of Canada
67
Royal Bank of Canada
Ontario, Canada
– -$1 -1 -3%
1 2
3

MREO Hedge Fund Activity: Q1 2023 in Review

58 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in Mereo BioPharma (MREO) for Q1 2023, worth a combined $43M — down 6.8% from $46.2M a quarter earlier.

Sellers outnumbered buyers: 10 funds closed out of MREO and 7 opened new positions — a net loss of 3 holders — while 14 trimmed existing stakes and 15 added.

The largest buyer was 683 Capital Management, adding an estimated $1.69M. The largest seller was OrbiMed, cutting an estimated $2.57M.

  • 58 institutional investors held Mereo BioPharma (MREO) as of Q1 2023, down from 61 in Q4 2022.
  • Funds reported $43M of Mereo BioPharma stock for Q1 2023, down 6.8% quarter-over-quarter.
  • 7 funds opened new Mereo BioPharma positions in Q1 2023 and 10 closed out, a net change of -3 holders.
  • The largest Mereo BioPharma buyer in Q1 2023 was 683 Capital Management, an estimated $1.69M added.
  • The largest Mereo BioPharma seller in Q1 2023 was OrbiMed, an estimated $2.57M sold.

Based on aggregated 13F filings for Q1 2023.